These box office numbers do not include the cost of production or marketing costs. They also don't count the billions in merchandising that Disney has made over the last...Entertainmentread more
Stocks in Asia traded lower on Monday morning, as investors await the start of a Nasdaq-style technology board on the Shanghai Stock Exchange.Asia Marketsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
Last week shows that oil prices are not the indicator for Middle East tensions they once were, and worries about global demand and growing U.S. production has changed that...Market Insiderread more
The firing of the tear gas was the latest confrontation between police and protesters who have taken to the streets for over a month to fight a proposed extradition bill and...China Politicsread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
Gluskin Sheff's David Rosenberg is painting a painful picture for stocks as earnings season goes into full gear.Futures Nowread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
Bayer's adjusted core earnings were flat for the quarter, as better prescription numbers for cardiovascular drug Xarelto were tempered by a weaker animal health business and a strong euro weighing on the value of overseas sales.
Third-quarter earnings before interest, tax, depreciation and amortization (EBITDA), adjusted for one-off items, came in at 2.2 billion euros ($2.5 billion), the company said on Tuesday, above an average estimate for 2.05 billion in a Reuters poll of analysts.
Bayer's best-selling stroke prevention drug Xarelto contributed to the positive surprise with a better-than-expected 933 million euros in quarterly sales, helped by a wider range of health conditions for which the pill can be prescribed.
Animal Health earnings almost halved to 44 million euros mainly because U.S. pet owners had brought the purchase of Advantage flea, tick and worm control products forward to the first half of the year, it said.
Earnings from the newly acquired Monsanto business played a lesser role because only about 20 percent of full-year EBITDA from that business are typically generated during the second half of the year, due to the seasonality of farming.
Bayer said the number of U.S. plaintiffs seeking damages over claims that Monsanto's Roundup and Ranger Pro herbicides can cause cancer had risen to 9,300, up from 8,700 reported previously.
It confirmed a forecast for adjusted core earnings per share for 2018 to decline to 5.70 to 5.90 euros, from 6.64 euros in 2017.